Skip to main content

Table 3 Xenoestrogenic and xenoandrogenic transactivities of the serum POP fraction

From: Xenohormone transactivities are inversely associated to serum POPs in Inuit

  

Male serum

Female serum

  

Nuuk

Sisimiut

Qaanaaq

All

Nuuk

Sisimiut

Qaanaaq

All

XER RLU/μg protein

n

32

51

36

119

45

42

32

118

 

median

1.00

0.95

0.97

0.97

1.05

0.90

1.01

0.99

 

mean ± SD

1.00 ± 0.08

0.94 ± 0.08

0.98 ± 0.09

0.97 ± 0.09

1.03 ± 0.08

0.94 ± 0.23

1.00 ± 0.10

0.99 ± 0.16

 

% agonistic

6

2

14

7

4

5

6

5

 

% decreased

9

33

25

24

9

20

28

18

 

P-value*

.09

.59

.24

.07

    
 

P-value**

.02 (Nuuk and Sisimiut different)

.001 (Sisimiut different)

XERcomp RLU/μg protein

n

32

51

38

121

45

42

32

118

 

median

0.97

0.82

0.93

0.89

1.03

0.96

0.91

0.96

 

mean ± SD

0.99 ± 0.09

0.84 ± 0.09

0.91 ± 0.12

0.90 ± 0.12

1.02 ± 0.11

0.95 ± 0.13

0.90 ± 0.12

0.96 ± 0.13

 

% further increased

6

2

0

3

34

10

6

14

 

% antagonistic

16

75

37

47

34

0

50

23

 

P-value*

.19

<.001

.76

<.001

    
 

P-value**

<.001 (all different)

<.001 (Nuuk different)

XAR RLU/μg protein

n

34

33

38

110

41

28

33

102

 

median

1.21

1.12

1.13

1.16

1.14

0.99

1.01

1.06

 

mean ± SD

1.22 ± 0.27

1.20 ± 0.29

1.16 ± 0.27

1.20 ± 0.27

1.17 ± 0.29

1.01 ± 0.18

1.09 ± 0.27

1.10 ± 0.26

 

% agonistic

18

22

11

17

15

0

12

10

 

% decreased

6

3

0

3

2

0

0

1

 

P-value*

.50

.01

.22

.01

    
 

P-value**

.47 (no post hoc test)

.07 (no post hoc test)

XARcomp RLU/μg protein

n

34

33

38

110

41

28

33

102

 

median

1.38

1.17

0.84

1.17

0.94

0.80

0.84

0.87

 

mean ± SD

1.40 ± 0.27

1.24 ± 0.37

0.90 ± 0.22

1.18 ± 0.36

0.99 ± 0.22

0.81 ± 0.13

0.86 ± 0.21

0.90 ± 0.21

 

% further increased

50

17

5

23

5

0

6

4

 

% antagonistic

0

6

24

11

12

25

21

19

 

P-value*

<.001

<.001

.49

<.001

    
 

P-value**

<.001 (all different)

.001 (Nuuk different)

XAR/XER

n

28

33

33

99

41

28

29

98

 

mean ± SD

1.19 ± 0.27

1.29 ± 0.34

1.19 ± 0.28

1.23 ± 0.30

1.14 ± 0.27

1.09 ± 0.24

1.08 ± 0.25

1.11 ± 0.25

 

P-value*

.51

.02

.09

.004

    
 

P-value**

.46 (no post hoc test)

.64 (no post hoc test)

XARcomp/XERcomp

n

28

33

34

100

41

28

29

98

 

mean ± SD

1.41 ± 0.29

1.50 ± 0.47

1.03 ± 0.31

1.33 ± 0.43

0.98 ± 0.22

0.89 ± 0.20

0.96 ± 0.26

0.95 ± 0.23

 

P-value*

<.001

<.001

.36

<.001

    
 

P-value**

<.001 (Qaanaaq different)

.30 (no post hoc test)

  1. XER and XAR: ER and AR transactivity of serum extract alone, respectively; XERcomp and XARcomp: competitive receptor transactivity upon co-treatment with EC50 of E2 or R1881, respectively.
  2. % agonistic and % decreased indicates a significant increase or decrease, respectively, for the XER and XAR activity compared to the activity of the solvent control which was set to 1. % further increased and % antagonist indicates a further significant increase or decrease, respectively, for the XERcomp and XARcomp transactivity compared to the transactivity of the E2-EC50or R1881-EC50 solvent control, which was set to 1.
  3. RLU/μg protein: The determined luciferase activity was corrected for cell density using protein measurements and expressed in relative luciferase units per microgram protein (RLU/μg protein).
  4. *: p value for men compared to women within the same district (e.g. Nuuk men and Nuuk women) using Student's t-test.
  5. **: p value for comparison between the districts for the separate genders (e.g. Nuuk vs Sisimiut vs Qaanaaq and vice versa) using ANOVA, result in the brackets (post hoc LSD/Dunnett T3 test).
Back to article page

Environmental Health

ISSN: 1476-069X